FDNA Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$27.5M
- Investors
-
3
FDNA General Information
Description
Developer of an AI-based phenotyping technology designed to analyze relevant genomic and phenotypic information. The company's technology detects physiological patterns that reveal disease-causing genetic variations, which are analyzed and included in their comprehensive database of clinically relevant genomic and phenotypic information, enabling clinicians, labs, and researchers to address genetic disease problems in healthcare.
Contact Information
Website
www.fdna.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Primary Office
- 490 Sawgrass Corporate Parkway
- Suite 200
- Sunrise, FL 33325
- United States
+1 (954) 000-0000
FDNA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series B) | $27.5M | 000.00 | 00000 | Completed | Generating Revenue |
FDNA Patents
FDNA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10667689-B2 | Systems, methods, and computer-readable media for patient image analysis to identify new diseases | Active | 08-Jun-2017 | 0000000000 | |
| US-20190261854-A1 | Systems, methods, and computer-readable media for patient image analysis to identify new diseases | Active | 08-Jun-2017 | 000000000 | |
| US-20180353072-A1 | Systems, methods, and computer-readable media for gene and genetic variant prioritization | Active | 08-Jun-2017 | 000000000 | |
| US-10327637-B2 | Systems, methods, and computer-readable media for patient image analysis to identify new diseases | Active | 08-Jun-2017 | 000000000 | |
| US-10470659-B2 | Systems, methods, and computer-readable media for gene and genetic variant prioritization | Active | 08-Jun-2017 | G06V10/82 |
FDNA Executive Team (12)
FDNA Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Assaf Segal | Self | Board Member | 000 0000 |
| Karen Madden | Self | Board Observer | 000 0000 |
| Moti Shniberg | Self | Co-Founder & Chairman | 000 0000 |
| Robin Woodhead | FDNA | Board Member | 000 0000 |
FDNA Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
FDNA Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Clal Biotechnology Industries | Venture Capital | Minority | 000 0000 | 000000 0 | |
| HCS Capital (Israel) | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Nacre Capital | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |